Inhibitory effect of antipsychotic drugs on the Con A- and LPS- induced proliferative activity of mouse splenocytes: A possible mechanism of action

Journal of Physiology and Pharmacology

Volumn 57, Issue 2, 2006, Pages 247-264

  Basta Kaim, A ^a   Budziszewska, B ^a   Jagla G ^b   Nowak, W ^b   Kubera, M ^a   Lason W ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Antipsychotic drugs; Proliferative activity of splenocytes; Protein kinases

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; CONCANAVALIN A; GLYCOGEN SYNTHASE KINASE 3; HALOPERIDOL; LIPOPOLYSACCHARIDE; NEUROLEPTIC AGENT; PROMAZINE; PROTEIN KINASE B; RACLOPRIDE; REMOXIPRIDE; RISPERIDONE; THIORIDAZINE; WORTMANNIN;

ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; DRUG MECHANISM; ENZYME ACTIVITY; MALE; MOUSE; NONHUMAN; SPLEEN CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; ANIMALS; ANTIPSYCHOTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CLOZAPINE; CONCANAVALIN A; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOGEN SYNTHASE KINASE 3; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; PHENOTHIAZINES; PHOSPHORYLATION; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-AKT; SPLEEN;

EID: 33746046431     PISSN: 08675910     EISSN: 08675910     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Descotes J, Tedone R, Evreux JCL. Different effects of psychotropic drugs on delayed hypersensitivity responses in mice. J Neuroimmunol 1985; 9: 81-85.
2. Maes M, Meltzer HY, Bosmans E. Immunoinflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 1994; 89: 346-351.
3. Jones PB, Rantakallio P, Hartikainen AL, Isohanni M, Sipila P. Schizophrenia as a long-term outcome of pregnancy, delivery, and perinatal birth cohort. Am J Psychiatry 1998; 155: 355-364.
4. Benes FM. Emerging principles of altered neural circuitry in schizophrenia. Brain Res Brain Res Rev 2000; 31: 251-269.
5. Yamaguchi K, Sawada T, Naraki T, et al. Detection of borna disease virus-reactive antibodies from patients with psychiatric disorders and from horses by electrochemiluminescence immunoassay. Clin Diag Lab Immunol 1999; 6: 696-700.
6. Rothermundt M, Arolt V, Bayer TA. Review of immunological and immunopathological findings in schizophrenia. Brain Res Immunol 2001; 15: 319-339.
7. Toomla O, Toomaspoeg L. Immunoglobulin concentartions in schizophrenic patients in relation to psychopathology. Nord J Psychiatry 1996; 50: 49-53.
8. Masserini C, Vita A, Basile R, et al. Lymphocyte subsets in schizophrenic disorders. Relationships with clinical, neuromorphological and treatment variables. Schizophr Res 1990; 3: 269-275.
9. Muller N, Riedel M, Ackenheil M, Schwarz MJ. Cellular and humoral immune system in schizophrenia: a conceptual re-evaluation. World J Biol Psychiatry 2000; 1: 173-179.
10. Katila H, Appelberg B, Hurme M, Rimon R. Plasma levels of interleukin -1β and interleukin-6 in schizophrenia, other psychoses and affective disorders. Schizophr Res 1994; 12: 29-345.
11. Lin A, Kenis G, Bignotti S, et al., The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin - 6. Schizophr Res 1998; 32: 9-15.
12. Song C, Lin A, Kenis G, Bosmans E, Maes M. Immunosuppressive production of interleukin - 1 receptor antagonist. Schizophr Res 2000; 42: 157-164.
13. Maes M, Bocchio Chiavetto L, Bignotti S, et al. Increased serum interleukin-8 and intereleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozpaine on serum leukemia inhibitory factor receptor. Schizophr Res 2002; 54: 281-291.
14. Basta-Kaim A, Kubera M, Budziszewska B, Siwanowicz J, Lasoń W. Effect of some antipsychotic drugs on immunoreactivity in C57BL/6 mice. Pol J Pharmacol 2002; 54: 737-742.
15. Ferguson RM, Schmidtke JR, Simmons RL. Concurrent inhibition by chlorpromazine of concanavalin-A induced lymphocyte aggregation and mitogenesis. Nature 1975; 256: 744-745.
16. Rapaport MH, McAllister CG, Kirch DG, Pickar D. The effect of typical and atypical neuroleptics on mitogen-induced T lymphocyte responsiveness. Biol Psychiat 1990; 29: 715-717.
17. Roudebush RE, Berry PL, Layman NK, Butler LD, Bryant HU. Dissociation of immunosuppression by chlorpromazine and trifluoroperazine from pharmacologic activities as dopamine antagonists. Int J Immunopharmacol 1991; 13: 961-968.
18. Baker GA, Santalo R, Blumenstein J. Effects of psychotropic agents upon the blastogenic response of human T-lymphocytes. Biol Psychiat 1997; 12: 159-169.
19. Karege F, Schwald M, El Kouaissi R. Drug-induced decrease of protein kinase a activity reveals alteration in BDNF expression of bipolar affective disorders. Neurophsychopharmacol 2004; 29: 805-812.
20. Basta-Kaim A., Budziszewska B, Jaworska-Feil L, et al. Inhibitory effect of imipramine on the human corticotropin-releasing-hormone gene promoter activity operates through a PI3-K/Akt mediated pathway. Neuropharmacol 2004; 49: 156-164.
21. Hinze-Selch D, Becker EW, Stein GM, et al. Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacol 1998; 19: 114-122.
22. Baker I, Masserano J, Wyatt RJ. Serum cytokine concentrations in patients with schizophrenia. Schizophr Res 1996; 20: 199-203.
23. 51Cr release assay of clozapine-induced cytotoxicity: evidence for immunogenic mechanism. J Clin Psychiatry 1994; 55: 143-148.
24. Leykin I, Mayer R, Shinitzky M. Short- and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacol 1997; 37: 75-86.
25. Moller HJ. Definition, psychopharmacological basis and clinical eveluation of novel/atypical neuroleptics: methological issues and clinical consequences. World J Biol Psychiatry 2000; 1: 75-91.
26. Kaisho T, Akira S. Critical roles of Toll-like receptors in host defence. Crit Rev Immunol 2000; 20: 393-405.
27. Rincon M, Flavell RA, Davis RA. The JNK and p38 MAP kinase signaling pathways in T cell-mediated immune responses. Free Rad Biolo Medicine 2000; 28: 1328-1337.
28. Takeuchi O, Akira S. Toll-like receptors; their physiological role and signal transduction system. Int Immunopharmacol 2001; 1: 625-635.
29. Silberman DM, Zorrilla-Zubilete M, Cremaschi GA, Genaro AM. Protein kinase C-dependent NF-κB activation is altered in T cells by chronic stress. Cell Molec Life Sciences 2005; 62: 1744-1754.
30. Ga̧dek-Michalska A, Spyrka J, Bugajski J. Psychological stress affects the involvement of prostaglandins and nitric oxide in lipopolysaccharide-induced hypothalamic-pituitary-adrenel response. J Physiol Pharmacol 2005; 56: 287-298.
31. Boukhris W, Kouassi E, Revillard JP. Differential effect of mixed D1/D2 and selective D2 dopaminergic antagonists on mouse T and B lymphocytes proliferation and interleukin production in vitro. Immunopharmacol Immunotoxicol 1998: 10: 501-512.
32. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia. Nat Genet 2004; 36: 131-137.
33. Lu XH, Bradley RJ, Dwyer DS. Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38. Brain Res 2004; 1011: 58-68.
34. Lu XH, Dwyer DS. Second-generation antipsychotic drugs, olanzapine, quetiapine and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways. J Mol Neurosci 2005; 27: 43-64.
35. Basta-Kaim A, Budziszewska B, Jaworska-Feil L, et al. Chlorpromazine inhibits the glucocorticoid receptor-mediated gene transcription in a calcium dependent manner. Neuropharmacol 2002; 43: 1035-1043.
36. Pozzi L, Hakansson K, Usiello A, et al. Opposite regulation by typical and atypical antipsychotics of ERK1/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum. J Neurochem 2003; 86: 451-459.
37. Kang UG, Seo MS, Roh MS, Kim Y, Yoon SC, Kim YS. The effects of clozapine on the GSK-3-medaited signaling pathway. FEBS Lett 2004; 27: 115-119.
38. Browning JL, Patel T, Brandt PC, Young KA, Holcomb LA, Hicks PB. Clozapine and the mitogen-activated protein kinase signal transduction pathway: implications for antipsychotic actions. Biol Psych 2005; 57: 617-623.
39. Alimohamed H, Rajakumar N, Seah YH, Rushlow W. Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol Psych 2005; 57: 533-542.
40. Kozlovsky N, Amar S, Belmaker RH, Agam G. Psychotropic drugs affect Ser9-phosphorylated GSK-3beta protein levels in rodent frontal cortex. Int J Neuropsychopharmacol 2005; 28: 1-6.
41. Basta-Kaim A, Budziszewska B, Jaworska-Feil L, et al. Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in Neuro-2A cells - an involvement of protein kinases. Neuropsychopharmacol 2005; 31: 853-865.
42. Basta-Kaim A, Budziszewska B, Jaworska-Feil L, et al. Effects of lipopolysaccharide and chlorpromazine on glucocorticoid receptor-mediated gene transcription and immunoreactivity: a possible involvement of p38-MAP kinase. Europ Neuropsychopharmacol 2004; 14: 521-528.
43. Hadjimitova V, Bakalova R, Traykov T, Ohba H, Ribarov S. Effect of phenothiazines on protein kinase C- and calcium-dependent activation of peritoneal macrophages. Cell Biol Toxicol 2003; 19: 3-12.
44. Dwivedi Y, Pandey GN. Effects of treatment with haloperidol, chlorpromazine, and clozapine on protein kinase C (PKC) and phosphoinositide- specific phospholipase C (PI-PLC) activity and on mRNA and protein expression of PKC and PLC isozymes in rat brain. J Pharmacol Exp Ther 1999; 291: 688-704.